Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Henry

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 17, 2004
Tolerance of a short course of nevirapine, associated with 2 nucleoside analogues, in postexposure prophylaxis of HIVDavid Rey, Marialuisa Partisani, Georgette Hess-Kempf, et al.
Plos One|December 24, 2015
Predictors of Standard Follow-Up Completion after Sexual Exposure to HIV: Five-Year Retrospective Analysis in a French HIV-Infection Care CenterPierre Gantner, Michele Treger, Constance De Miscault, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2001
Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeksD Rey, M P Schmitt, M Partisani, et al.
Medecine Et Maladies Infectieuses|September 6, 2005
[Hepatitis A seroprevalence in HIV-infected patients]D Rey, E Frick-Michot, M Partisani, et al.
Scandinavian Journal of Infectious Diseases|September 18, 2014
Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort studyPierre Gantner, Christine Koeppel, Marialuisa Partisani, et al.
HIV Medicine|August 16, 2014
Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort studyP Gantner, S Reinhart, M Partisani, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 17, 2004
Tolerance of a short course of nevirapine, associated with 2 nucleoside analogues, in postexposure prophylaxis of HIVDavid Rey, Marialuisa Partisani, Georgette Hess-Kempf, et al.
Plos One|December 24, 2015
Predictors of Standard Follow-Up Completion after Sexual Exposure to HIV: Five-Year Retrospective Analysis in a French HIV-Infection Care CenterPierre Gantner, Michele Treger, Constance De Miscault, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2001
Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeksD Rey, M P Schmitt, M Partisani, et al.
Medecine Et Maladies Infectieuses|September 6, 2005
[Hepatitis A seroprevalence in HIV-infected patients]D Rey, E Frick-Michot, M Partisani, et al.
Scandinavian Journal of Infectious Diseases|September 18, 2014
Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort studyPierre Gantner, Christine Koeppel, Marialuisa Partisani, et al.
HIV Medicine|August 16, 2014
Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort studyP Gantner, S Reinhart, M Partisani, et al.
Pageof 3